|
Dr. Freytag brings to his role as Chairman and CEO of Aspreva an impressive background that includes several executive and senior management positions in pharmaceutical and biopharmaceutical companies. In these positions he demonstrated his ability to successfully plan, execute and lead clinical and business development strategies for the benefit of those companies as they evolved and grew.
Most recently, from 1998 until 2006, Dr. Freytag was President, CEO and Chairman of Myogen, Inc., a biopharmaceutical company. During his tenure at Myogen, he helped start and capitalize the company, and led the company through significant growth until it was acquired in November 2006 by Gilead Sciences (GILD) for $2.5 billion. Prior to Myogen, Dr. Freytag held a number of senior executive and management posts in companies such as Somatogen, Inc., Boehringer Mannheim Corporation and E.I. DuPont de Nemours & Co. His experience in these companies includes research and development, business operations, strategic planning and business development.
Dr. Freytag also has significant experience as a member of the Board of Directors for a number of companies. He currently serves on the Board of Directors for Immunicon Corporation, ARCA Discovery, Inc. and the Colorado BioScience Association.
Dr. Freytag earned his Ph.D. from the University of Kansas Medical Center and completed a postdoctoral fellowship at the Duke University Medical Center. | 